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Intravesical instillation of Bacillus Calmette-Guerin (BCG) is a treatment to prevent recurrence of superﬁcial urothelial bladder
carcinoma. Complications after bladder instillation of BCG have been reported including locally invasive and systemic infections
due to dissemination of Mycobacterium bovis from the bladder. We present an uncommon case and literature review of prosthetic
joint infection due to M. bovis after intravesical BCG treatment of bladder cancer.
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1.Introduction
The Bacillus Calmette-Guerin (BCG) has been used as
intravesical immunotherapy for superﬁcial urothelial blad-
der carcinoma in preventing its recurrence [1]. How-
ever, this modality of treatment is not benign and may
have complications. Side eﬀects range from locally and
self-limited complications to systemic and life-threatening
adverse reactions [2]. Osteoarticular complications after
intravesical BCG instillation can present as infectious and
noninfectious, the latter being the most common [3].
An infectious osteoarticular complication of BCG, which
implies invasive M. bovis disease, is rare. We report a case
of invasive BCG disease causing prosthetic hip infection in
a patient, 19 months after intravesical BCG instillation for
superﬁcial bladder carcinoma. Other cases of prosthetic joint
infection due to BCG after treatment of bladder cancer were
also reviewed.
2.CaseReport
In June of 2007, an 82-years-old man with a history of right
total hip arthroplasty (THA), in 1997 due to osteoarthritis,
presented to his primary care physician (PCP) with right
hip pain. His past medical history was signiﬁcant for a
diagnosis of papillary urothelial carcinoma of the bladder in
June 2005 and a subsequent transurethral bladder resection
and BCG bladder instillation from July 2005 to October
2005. He received a total of 6 weeks of BCG instillation
at 50mg per dose, divided in two cycles of three weekly
doses separated by one month. The initial workup for the
presenting right hip pain showed loosening of hardware by
imaging (Figure 1). He denied fever, chills, night sweats, or
weight loss. His physical exam was unremarkable. His white
blood cell count was 8.8×103/µL (normal: 4.5–11×103/µL)
with 75% neutrophils, and his hemoglobin was 10.8g/dL
(normal: 13.8–18g/dL) with mean corpuscular volume of
92.2fL (normal: 80–95fL). He underwent exploration of
his right THA and purulent material (drainage) was found
in the joint. Intraoperative Gram stain was negative and
the THA was replaced. THA Gram stain showed rare
leukocytes, and multiple aerobic and anaerobic bacterial
cultures were negative. Acid fast bacilli (AFB) stain and
culture were not done on this initial exploration and
THA replacement. Erythrocyte sedimentation rate (ESR)
levels were not done preoperative; however, postoperative
ESR levels were 51mm/60 minutes (normal: 8–15mm/60
minutes). The patient was treated for culture negative septic2 International Journal of Microbiology
arthritis with eight weeks of ertapenem 1gram IV daily. In
December 2007, his right hip became indurated and tender.
One month later he developed a soft and erythematous
raised lesion at the site of the surgical wound. Amoxicillin-
clavulanic acid 875/125mg orally twice daily was prescribed
for 2 weeks by his PCP with no improvement.
In March 2008, a second right THA revision was
performed with the suspicion of a superﬁcial surgical wound
infection. However, purulent ﬂuid was found tracking
down from the surgical wound to the THA. Irrigation,
debridement, and replacement of the femoral head were
done. Again, intraoperative cultures of the hip were neg-
ative. Ertapenem 1gram IV daily was empirically started.
Intraoperative AFB stain from the right hip prosthesis was
negative; however, the mycobacteria culture was reported
positive for growth on day 39 of incubation. Mycobacterium
tuberculosis complex was identiﬁed by DNA probe (Gen-
Probe, San Diego, CA, USA). Isoniazid, rifampin, etham-
butol, and pyrazinamide were empirically started. No risk
factors for tuberculosis were identiﬁed. His chest X-rays
were unremarkable; a PPD was not done. Based on the
history and due to the high suspicion of M. bovis BCG
infection, the isolate was sent to a reference laboratory for
speciation. Using polymerase chain reaction methodology,
Mycobacterium bovis was identiﬁed and a deletion of the
RD1 region was noted conﬁrming M. bovis BCG strain.
Susceptibility testing showed resistance to pyrazinamide
only. Pyrazinamide and ethambutol were discontinued and
rifampin and isoniazid were continued. Since the patient
was deemed high surgical risk to undergo THA revision, the
patient was treated with antibiotics only and to be closely
followed up for any possible relapse. After 12 months on
treatment for M. bovis, the patient continues to improve
without signs of active infection in right THA.
3. Discussion
Calmette and Guerin started to develop tuberculosis vaccine
in 1908, and after multiple passages of virulent Mycobac-
terium bovis was attenuated [1]. In 1921, the BCG vaccine
was launched for immunization against tuberculosis in
humans. Soon it became evident that the BCG vaccine had
immunomodulating eﬀects in cancer patients. However, it
was not until 1976 when it was used clinically to treat
a patient with bladder cancer [1]. Since then, BCG has
been established as a routine immunomodulating agent for
superﬁcial bladder cancer and one of the treatments in
prevention of recurrent disease [4].
BCG bladder instillation can cause local and systemic
side eﬀects. After instillation, BCG will cause a local inﬂam-
matory reaction that can manifest as fever and hematuria.
These symptoms are self-limited and typically improve with
symptomatic treatment. Systemic adverse reactions due to
BCG bladder instillation can range from granulomatous
prostatitis to BCG sepsis with high mortality if not treated
[5].
Lammetal.reportedareviewofcomplicationsafterBCG
intravesical treatment of 2602 patients with bladder cancer
Figure 1: Anteroposterior X-rays of right hip showing lucencies
around femoral and acetabular prosthesis.
[6]. The most common complication was cystitis, followed
by fever and granulomatous prostatitis. Systemic BCG
infection deﬁned as pneumonitis or granulomatous hepatitis
occurred in 0.7% of patients who received intravesical BCG.
BCG sepsis was seen in 0.4% of patients with an estimated
mortality of 1 death per 12,500 patients.
Musculoskeletal complications from intravesical BCG
were reported to be rare by Lamm et al. [6]; however,
multiple cases have been reported over the years. The most
common complications included arthralgia and arthritis
which some authors have reported their occurence in 0.5
to 1% of patients [3]. This complication is thought to be a
reactive arthritis due to a systemic response of the host to the
BCG and not a direct invasion of the joint by the attenuated
M. bovis. Cultures are usually negative and the symptoms
usually respond to anti-inﬂammatory treatment.
Invasive BCG infection of muscle and bone structures
(with positive cultures) is rare but has been reported in
literature. Clavel et al. reviewed eight cases of M. bovis
osteoarticular infections after intravesical BCG including
septic arthritis, prosthesis joint infections, and discitis [7].
M. bovis arthroplasty infection without a history of BCG
exposure has been reported but it seems to be exceeded by
intravesical BCGs related prosthetic joint infections [8]. A
review of literature reveals four other cases of M. bovis pros-
thetic joint infections (Table 1). Patients had an average age
of 77 years at presentation, and they all had prosthetic joint
p r o c e d u r e s6t o1 2y e a r sp r i o rt ot h eB C Gt r e a t m e n t .M o s t
patients presented with subacute to chronic joint pain. For
the majority of the patients, the presumptive diagnosis was
aseptic prosthetic failure. Only one patient presented with
signs of acute infectious process with rigors and sweats [9].
Prosthetic joint infections can occur anytime from 7 days
to years after the intravesical treatment with BCG. Early
presentation of infection could be due to hematogenous
dissemination of M. bovis bladder instillation. This has been
minimized by delaying treatment for at least 2 weeks afterInternational Journal of Microbiology 3
Table 1: Case reports of M. bovis prosthetic joint infections after intravesical BCG instillation in patients with bladder cancer.
Case report Age/sex Orthopedic
procedure
Bladder cancer
(months PTP)
BCG strain
and duration
of bladder
cancer
treatment
Clinical
presentation
Cultures/drug
susceptibilities Treatment/condition
Our patient 82, male Right THR 20 Tice BCG, 6
weeks
Right hip
pain
M. bovis;s e n s i t i v e
to INH, RIF, ETM.
Resistant to PZA
1-Stage THR,
INH/RIF × 1 year.
Alive and free of
symptoms at 1 year
Reigstad and
Siewers (2008)
[10]
86, male Left THR 10 Oncotice
BCG, 9 weeks
Aseptic
loosening of
hardware
M. bovis;s e n s i t i v e
to INH, RIF, PZA
1-stage THA
revision, INH, RIF,
PZA × 6m o n t h s ,
INH/RIF × 6
months, and INH ×
1 year of
consolidation
Segal and Krauss
(2007) [11] 76, male Left THR 48
Multiple
treatments.
Strain NR
Groin pain
M. bovis;
susceptibilities
unknown
INH/RIF/ETM × 1
year. 2-stage
arthroplasty. Alive
and free of
symptoms.
Guerra et al.
(1998) [12] 66, male Right THR 12
Tice BCG, 12
weeks, radical
cystectomy
Hip pain,
rigors and
sweats
M. bovis;
susceptibilities
unknown
INH/RIF × 6
months and 2-stage
arthroplasty. Patient
died due to his
underlying
condition.∗
Chazerain et al.
(1993) [9] 77, male Left TKR 2.5 Pasteur BCG Acute
arthritis
M. bovis;
susceptibilities
unknown
2 antituberculous
drugs (NR) × 2
years and 2-stage
arthroplasty. Alive
and free of
symptoms.
Abbreviations: prior to presentation (PTP), total hip replacement (THR), total knee replacement (TKR), not reported (NR), isoniazid (INH), rifampin (RIF),
and ethambutol (ETM).
∗Death due to lung cancer.
surgical resection of the bladder tumor and by avoiding
traumatic catheterization of the bladder [2].
Explaining the acquisition of M. bovis prosthetic infec-
tions months after the treatment poses a challenge. This
may be explained by the persistence of mycobacteria in
the bladder with subsequent dissemination months after
treatment. Some studies have shown that 6 weeks after
treatment there are no viable mycobacteria in the bladder
[13]. However, Bowyer et al. found that ﬁve out of 90
patients had persistent mycobacteria in the urine up to
16.5 months after intravesical BCG treatment [13]. Breaches
in the mucosal and immunologic barrier can then occur
months after treatment.
Systemic persistence of M. bovis with later reactivation
and seeding of the prosthesis could account for the late pre-
sentation of our patient. B¨ ohle et al. reported a case of BCG
pulmonary infection 11 months after radical cystectomy in
a patient with bladder cancer treated with intravesical BCG
[14].TheauthorsproposedearlydisseminationofBCGfrom
the bladder, seeding the lungs and reactivation months later.
This also has been seen with intradermal BCG presenting
years later with lymphadenitis.
Treatment of BCG prosthetic joint infection is anecdotal
and not well deﬁned. Based on case reports of tuberculosis
infection of arthroplasties, Marmor et al. reported successful
treatment with antituberculous drugs along with surgical
procedures [15]. Antituberculous regimen included at least 3
drugs ranging from 6 to 8 months. Most cases require a two
stage revision arthroplasty along with chemotherapy. One
stage revision arthroplasty and even retention of prosthesis
with synovectomy and debridement have been reported with
good outcomes [16]. Spinner et al. found that late onset
of tubercular prosthesis infections often tend to fail with
retention of the hardware [17].
From the review of the literature (Table 1), three out of
four patients with M. bovis prosthetic joint infections were
treated with two stage arthroplasty replacement, with one
treatment failure. The treatment failure was noted to have
persistent infection by pathology but negative cultures after
six months of antituberculous drugs treatment [12]. Two4 International Journal of Microbiology
patients underwent a one-stage arthroplasty replacement
with good outcome, including our patient [10].
Antituberculous drugs used to treat BCG infections
include isoniazid, rifampin, ethambutol, and cycloserine.
M. bovis has been noted to have intrinsic resistance to
pyrazinamide in vitro, and therefore, this drug is never
recommended in the treatment of BCG infections. Isoniazid,
rifampin, and ethambutol suppressed mycobacterial growth
by day 7 of treatment, and cycloserine inhibits growth of
M. bovis by 24 hours in animal studies [2]. However, a
recent study showed increased cycloserine resistance in BCG
M. bovis strains [18]. As most BCG prosthesis infections
presented in a subacute/chronic course, treatments would
typically include a four-drug regimen with ﬁrst-line antitu-
berculous drugs followed with deescalation to two or three
drugs once M. bovis has been identiﬁed by culture.
Durationoftreatmenthasalsovariedinthediﬀerentcase
reports. On average, patients receive a minimum of one-year
treatment.Treatmentoflessthanoneyearmayleadtofailure
as in the case reported by Guerra et al. [12]. Failure was
determined by histopathology showing granulomas contain-
ing ﬂuorescent bacilli although mycobacterial cultures were
negative.
Patients with prosthetic joint infections and bladder
cancer treated with intravesical BCG may be at risk for M.
bovis prosthetic joint infection. Some authors suggest the use
of antituberculous prophylaxis in patients with indwelling
prosthetic devices who undergo intravesical BCG treatment
[19]. However, due to few cases of indwelling prosthetic
infections with M. bovis after intravesical BCG instillation,
the beneﬁts of prophylaxis remain uncertain. Which drug to
choose for prophylaxis also remains uncertain.
M. bovis prosthetic hip infection after BCG intravesical
instillation is a rarely reported condition. Medical and/or
surgical treatments need to be further investigated and
clariﬁed. With the increase in the aging population, the
likelihood patients with prosthetic joints being treated with
BCG instillation should alert the physician of the possibility
of this infection.
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